These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7749791)

  • 1. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
    Schacker T; Collier AC; Coombs R; Unadkat JD; Fox I; Alam J; Wang JP; Eggert E; Corey L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):145-52. PubMed ID: 7749791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma viremia in human immunodeficiency virus infection.
    Coombs RW; Collier AC; Allain JP; Nikora B; Leuther M; Gjerset GF; Corey L
    N Engl J Med; 1989 Dec; 321(24):1626-31. PubMed ID: 2511447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
    Clark SJ; Saag MS; Decker WD; Campbell-Hill S; Roberson JL; Veldkamp PJ; Kappes JC; Hahn BH; Shaw GM
    N Engl J Med; 1991 Apr; 324(14):954-60. PubMed ID: 1900576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia.
    Schacker T; Coombs RW; Collier AC; Zeh JE; Fox I; Alam J; Nelson K; Eggert E; Corey L
    J Infect Dis; 1994 Jan; 169(1):37-40. PubMed ID: 8277195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    Stiehm ER; Fletcher CV; Mofenson LM; Palumbo PE; Kang M; Fenton T; Sapan CV; Meyer WA; Shearer WT; Hawkins E; Fowler MG; Bouquin P; Purdue L; Sloand EM; Nemo GJ; Wara D; Bryson YJ; Starr SE; Petru A; Burchett S
    J Infect Dis; 2000 Feb; 181(2):548-54. PubMed ID: 10669338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.
    Henrard DR; Daar E; Farzadegan H; Clark SJ; Phillips J; Shaw GM; Busch MP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):305-10. PubMed ID: 7788430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 immunoadhesins in anti-HIV therapy: new developments.
    Chamow SM; Duliege AM; Ammann A; Kahn JO; Allen JD; Eichberg JW; Byrn RA; Capon DJ; Ward RH; Ashkenazi A
    Int J Cancer Suppl; 1992; 7():69-72. PubMed ID: 1428410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T
    An Med Interna; 1999 Sep; 16(9):447-50. PubMed ID: 10609356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR; Liebmann JM; Huang XL; Fan Z; Al-Shboul Q; McMahon DK; Day RD; Riddler SA; Mellors JW
    J Infect Dis; 1999 Feb; 179(2):329-36. PubMed ID: 9878015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.
    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C; Colimon R; Cartier F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):243-8. PubMed ID: 7788423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently.
    Yamaguchi K; Sugiyama T; Kato S; Kondo Y; Ageyama N; Kanekiyo M; Iwata M; Koyanagi Y; Yamamoto N; Honda M
    J Med Virol; 2008 Aug; 80(8):1322-31. PubMed ID: 18551617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.